「etc.research」の検索結果
71件：16～20件目を表示
もしかして
-
お知らせ | 千寿製薬株式会社
December 22, 2025 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation chann
http://www.senju.co.jp/english/news/ -
Presence of Products | Overseas Activities | SENJU Pharmaceutical
Asia Middle East Europe North&South Ameica Asia India Brand Name Marketing Authorisation Holder JP Brand Name GLUCOTIM－LA Centaur Pharmaceuticals PVT LTD Not marketed in JP Korea Brand Name Market
http://www.senju.co.jp/english/global/world.html -
Data And Statistics | About Senju | SENJU Pharmaceutical
Sales Revenue 2021.3 2022.3* 2023.3* 2024.3* 2025.3* Sales Revenue 40.7 40.8 46.4 48.9 48.9 Operating Profit 5.4 6.9 7.4 7.1 2.4 Ordinary Profit 8.0 9.1 8.7 9.1 2.9 Total Assets 75.8 83.9 88.2 98.4 10
https://www.senju.co.jp/english/about/sales.html -
Presence of Products | Overseas Activities | SENJU Pharmaceutical
Asia Middle East Europe North&South Ameica Asia India Brand Name Marketing Authorisation Holder JP Brand Name GLUCOTIM－LA Centaur Pharmaceuticals PVT LTD Not marketed in JP Korea Brand Name Market
https://www.senju.co.jp/english/global/world.html -
Overseas Activities | SENJU Pharmaceutical
Eye health and pharmaceutical development have no borders. We engage in international activities with a view to the future of pharmaceuticals, transcending national and corporate boundaries. As we ent
https://www.senju.co.jp/english/global/